SURMOUNT-2: Tirzepatide in Diabetic and Obese Patients

The SURMOUNT-2 study demonstrates that tirzepatide is equally effective in patients combining type 2 diabetes and obesity, with major glycemic benefits. Following the spectacular results of SURMOUNT-1 in non-diabetic patients, the question arose: would tirzepatide be as effective in patients simultaneously presenting with type 2 diabetes … Read more

SURMOUNT-1 Study: Detailed Weight Loss Results with Tirzepatide

The SURMOUNT-1 study laid the scientific foundation for the use of tirzepatide in obesity. A detailed analysis of the game-changing results. Published in the New England Journal of Medicine in July 2022, the SURMOUNT-1 study is the pivotal clinical trial that led to the authorization of tirzepatide (Zepbound) for the treatment of obesity. With 2,539 participants … Read more

Survodutide, retatrutide, orforglipron: The Next Generation After Mounjaro

Survodutide, retatrutide, orforglipron: molecules that could surpass Mounjaro are already in advanced clinical trials. While tirzepatide (Mounjaro/Zepbound) has revolutionized obesity treatment with its dual GIP/GLP-1 action, pharmaceutical research doesn’t stop. Several new-generation molecules are under development, promising even more impressive results. An overview of treatments that could redefine obesity management in the coming years. Read more

Why Tirzepatide Acts on the Liver, Pancreas, and Brain

Tirzepatide does more than just reduce appetite: it simultaneously acts on three vital organs to combat obesity and type 2 diabetes. Tirzepatide, the active ingredient in Mounjaro and Zepbound, is often presented as a simple injectable appetite suppressant. This reductive view ignores the complexity of its mechanism of action. In reality, this … Read more